A Phase 4 interventional study of Losartan and Placebo in ACL Injury, ACL Reconstruction and Scar Formation, sponsored by Rush University Medical Center. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Rush University Medical Center · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 176 studies in Anterior Cruciate Ligament Injuries with a site in United States — 44 open to participants now, 62 under way, 3 of them phase 3. Anterior Cruciate Ligament Injuries · United States.
Among the 176 studies in Anterior Cruciate Ligament Injuries with a site in United States, this one is the 19th largest by planned enrollment of the 152 interventional ones that give a count, is one of 2 that started in 2027, is one of 16 in phase 4, reaches primary completion later than 49 of the 61 other live ones, and was the 169th registered.
627 studies on the registry are indexed under Anterior Cruciate Ligament Injuries; 193 are open to participants now.
Browse Anterior Cruciate Ligament Injuries studies →44 of the 176 studies in Anterior Cruciate Ligament Injuries with a site in United States are open now. Recruiting first, the newest first:
Stanford University · Sites in United States
Ages 13–17
Wake Forest University Health Sciences · Sites in United States
Ages 14–39
University of Michigan · Sites in United States
Ages 14–45
CONMED Corporation · Sites in United States
Ages 14–70
Spaulding Rehabilitation Hospital · Sites in United States
Ages 18–55
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 122 Anterior Cruciate Ligament Injuries studies recruiting now, 27 (22%) set no upper age limit and 92 (75%) stop at 75 or younger; 46 take children under 18; 21 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
176 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 10 · Phase 3 9 · Phase 4 16
First in 2001; this study’s year is marked. 2 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 144 is above the median of 56 across 460 interventional studies indexed under Anterior Cruciate Ligament Injuries.
Median enrollment 50 across the 152 interventional studies, 202 across the 24 observational. Of the 97 that completed or were terminated, 42 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 176 have an industry lead sponsor. The 10 most frequent:
Rush University Medical Center is the lead sponsor of 397 studies on the registry; 60 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 26 (81%) have results posted.
Rush University Medical Center has 4 studies filed under Anterior Cruciate Ligament Injuries — fewer than ten, so there is no comparison to draw.
22 of the studies in Anterior Cruciate Ligament Injuries with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05412381Phase 3Hospital for Special Surgery, New YorkPRP in ACLR to Prevent PTOA | 2026-12-31 |
| NCT06529692University of MichiganMichigan Split-belt Treadmill Training Program to Improve Long-Term Knee Biomechanics After ACL Reconstruction | 2026-12 |
| NCT05488054University Hospitals Cleveland Medical CenterMuscle O2 Saturation and Hemoglobin Levels During Rehabilitation From Arthroscopic Surgery | 2026-12 |
| NCT05965310Henry Ford Health SystemAnterior Cruciate Ligament Recovery With Virtual Psychological Intervention | 2027-01 |
| NCT03968913University of California, Los AngelesBiologic Therapy to Prevent Osteoarthritis After ACL Injury | 2027-01-30 |
Add all 22 to your calendar (.ics) → With an account.
Among the 176 studies in Anterior Cruciate Ligament Injuries with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study to investigate the effect of using losartan (a blood pressure lowering drug with anti-scarring properties) on preventing primary postoperative arthrofibrosis (formation of abnormal scar tissue) in the knees in participants undergoing anterior cruciate ligament (ACL) repair surgery of their knee.
Losartan, an angiotensin-II receptor blocker (ARB), approved by the Food and Drug Administration (FDA) for the treatment of hypertension and diabetic nephropathy, has garnered recent interest in the field of orthopedic surgery as an anti-fibrotic (anti-scarring) agent. Losartan's primary mechanism of action as an anti-hypertensive involves acting as a receptor antagonist for angiotensin II, a peptide produced by the liver which causes vasoconstriction, release of anti-diuretic hormone from the pituitary gland, and release of aldosterone from the adrenal glands, among other functions. Losartan secondary function is to act as a TGF-β1 blocker. TGF-β1 has been implicated in pro-fibrotic pathways in multiple organs systems. Losartan, initially as a treatment for hypertension and diabetic nephropathy, was found to have benefits against fibrosis in the renal system. As a result, the use of losartan has gained interest in several other fields in medicine, including plastic surgery for wound healing and keloid prevention, in ophthalmology to prevent corneal scarring, and orthopedic surgery. The potential use of losartan presents an attractive anti-fibrotic prophylaxis candidate against the formation of postoperative arthrofibrosis following ACLR.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The experimental arm (Arm 1) will receive 25mg losartan daily for 3 days followed by 50 mg losartan daily for 25 days.
Drug: Losartan
The placebo arm (Arm 2) will receive a placebo tablet with the same appearance and frequency to that of the losartan group.
Other: Placebo
Two types of losartan capsules will be compounded by combining a broken-up 25mg or 50mg losartan tablet and microcrystalline cellulose placebo filler to eliminate rattling of the broken tablet inside of the capsule. The 25mg losartan capsules will be yellow and the 50 mg losartan capsules will be blue.
The placebo capsules will consist of microcrystal cellulose and will come in yellow and blue to appear identical to the losartan capsules.
Range of Motion
Range of motion measured from baseline to 12 months
Time frame: 12 months
PDFs hosted by the registry, ClinicalTrials.gov.
Start is estimated for Aug 2027; primary completion for Oct 2028, 14 months later.
Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Aug 2027, on Nov 19, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Losartan
Anterior Cruciate Ligament Injuries →
Rush University Medical Center →